Prisciandaro M, et al. – In this study, researchers investigated the safety and efficacy of cabozantinib for the treatment of patients with nonclear cell renal cell carcinoma (RCC). They analyzed data collected across 24 Italian hospitals from 17 adults with advanced nonclear cell RCC, with an Eastern Cooperative Oncology Group Performance Status score of 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Eleven patients started with 60-mg cabozantinib, which was administered orally once-daily in 28 days cycles. Toxicity led to dose reductions to 40 mg or 20 mg. Type I papillary RCC, type II papillary, chromophobe, and Bellini duct carcinoma was detected in 3 (18%), 9 (53%), 3 (18%), and 2 (11%) patients, respectively. Findings revealed activity as well as safety of cabozantinib as a treatment option, with 7.83 months of median progression-free survival and about 60% 1-year overall survival. The most frequent adverse events (AEs) experienced were asthenia (41%), diarrhea (35%), aminotransferase increasing (35%), mucosal inflammation (35%), hand and foot syndrome (24%), and hypothyroidism (24%). Grade 3 and 4 AEs were noted in 41% of patients.